In Brief: SmithKline Beecham/Pfizer
SmithKline Beecham/Pfizer: Complete the sale of SB's worldwide animal health business to Pfizer Jan. 19. The agreement was announced Nov. 23. Pfizer pays $1.45 bil. in cash for the business, which had 1993 worldwide sales of $614 mil., operating profit of $104 mil. and net assets of $348 mil, according to SB...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth